Answers are grounded in this paper and cite their sources.
Case report shows delayed diagnosis of neuroleptic malignant syndrome after droperidol use in a patient with substance use disorder, indicating urgent awareness required.
Introduction Droperidol, a first generation anti-psychotic, is commonly used as an antiemetic, sedative, and adjunct to anesthesia. As an antidopaminergic agent, it carries the risk of precipitating Neuroleptic Malignant Syndrome (NMS). NMS is a rare and potentially fatal reaction to dopamine-receptor blockade characterized by hyperthermia, “lead-pipe” rigidity, altered mental status, and autonomic dysfunction. There are few cases of droperidol-induced NMS in the literature, in addition when droperidol is given as an antipsychotic or perioperatively, clinicians may be more primed to suspect NMS. We present a case wherein the patient was given droperidol as an antiemetic and diagnosis of NMS was delayed. Case A 38-year-old female with a past medical history of drug and alcohol use disorder presented with syncope. In the ED she developed nausea and vomiting, for which she was given one dose of IV droperidol 1.25 mg. Subsequently, she had an acute dystonic reaction treated with IV diphenhydramine. However, she quickly became hyperthermic, diaphoretic, tachycardic and tachypnic to the 50s. These symptoms were initially attributed to withdrawal and she was treated with phenobarbital and suboxone with no improvement. She was intubated for tachypnea and airway protection and transferred to the ICU. The differential diagnosis included serotonin syndrome, malignant catatonia, drug intoxication, meningitis, encephalitis, seizures, tetanus, and thyrotoxicosis. Laboratory work-up was negative for infectious etiology and toxic ingestion of salicylates, acetaminophen, and alcohol. The urine toxicology screen was positive for fentanyl and cocaine, however, she had been in police custody for several hours prior to presentation. CT head was unremarkable and EEG demonstrated nonspecific severe encephalopathy. Taken together, her encephalopathy, prolonged hyperthermia, muscle rigidity, rhabdomyolysis, tachycardia, and tachypnea supported a diagnosis of NMS. She was treated with a midazolam infusion, which improved rigidity and fevers. She was extubated on day 6, and the hyperthermia resolved on day 10 of hospitalization. The patient was discharged to the community with complete resolution of symptoms. Discussion Here, we describe a case of NMS in a patient with significant substance use. Concerns for intoxication and withdrawal originally clouded her clinical picture, leading to a delay in diagnosis. While the association between antipsychotic medications and NMS is well known, usage of these medications for other purposes raises similar risks. We hope to alert non-psychiatric/anesthesia clinicians that even a single dose of droperidol can precipitate NMS.
No takes yet. Share an insight, caveat, or question.
Schwartz et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: